Project Grant HT94252510345
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$405K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Sunnyvale, CA 94089, USA
Similar Awards
This $405,000 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports Panorama Research Incorporated's development of a novel antibody-based immunotherapy to enhance ovarian tumor responses to treatment. The project aims to create a switchable split superantigen fused with antibodies targeting binary tumor-specific receptors, with the goal of boosting the effectiveness of immunotherapy for ovarian cancer patients. As a...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,098,194 project grant to Tilt Biotherapeutics OY to research novel cancer immunotherapies. The three-year project, titled "UNLEASHING THE FULL POTENTIAL OF CHECKPOINT INHIBITOR ANTIBODIES WITH T-CELL-STIMULATING ONCOLYTIC ADENOVIRUSES FOR TREATMENT OF OVARIAN CANCER", aims to develop a combination therapy using checkpoint inhibitor antibodies and oncolytic adenoviruses to...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
The federal Project Grant award of $954,000.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Massachusetts Institute of Technology (MIT) to develop tumor-targeted nanocarriers for effective immunomodulation of ovarian cancer. The award period runs from May 1, 2025 to April 30, 2028. The research aims to explore innovative approaches to cancer prevention, diagnosis, and treatment, with a focus on...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
This $1,290,499.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program will support the Dana-Farber Cancer Institute's research to enhance the antitumor activity of natural killer cells in ovarian cancer. The grant will fund a 4-year research project from September 1, 2024 to August 31, 2028 to investigate innovative approaches to treating ovarian cancer by leveraging the immune system's natural killer...
The Defense Health Agency awarded a $778,092 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant supports the advancement of preclinical studies for a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy to achieve cures for high-grade serous ovarian cancer. The project aims to develop innovative CAR-T cell-based immunotherapies to improve treatment outcomes for this...
The University of Southern California will receive $413,750 through September 2025 under a Project Grant from the Defense Health Agency to develop next-generation chimeric antigen receptor T cells targeting folate receptor 1 for the treatment of ovarian cancer. Funded through the Military Medical Research and Development program (CFDA 12.420), this award will support the grantee's applied medical research efforts to investigate innovative solutions for battlefield health care and transform...